We are international
Donate
TEXT SIZE   

2016 Annual Meeting of the American Society of Clinical Oncology (ASCO)
June 3-7, 2016
Chicago, Illinois

ASCO 2016

06.05.16   ASCO 2016: Multiple Myeloma Overview -- Dr. Morie Gertz

Dr. Morie Gertz from the Mayo Clinic Rochester, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.


06.04.16   ASCO 2016: Multiple Myeloma Overview -- Dr. Paul Richardson

Dr. Paul Richardson from the Dana-Farber Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.


06.05.16   ASCO 2016: Multiple Myeloma Overview -- Dr. Sagar Lonial

Dr. Sagar Lonial from the Winship Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.


06.04.16   ASCO 2016: Multiplem Myelom Überblick -- Dr. Katja Weisel

An overview of multiple myeloma presentations at ASCO 2016 by Dr. Katja Weisel of the Tubingen University, Tubingen, Germany.


06.06.16   ASCO 2016: Destacados de mieloma múltiple -- Dr. Maria-Victoria Mateos

An overview of multiple myeloma presentations at ASCO 2016 by Dr. Maria-Victoria Mateos of the University Hospital of Salamanca. Salamanca, Spain


06.06.16   ASCO 2016: CASTOR study -- Dr. Katja Weisel

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.


06.06.16   ASCO 2016: PAVO study -- Dr. Saad Usmani

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma


06.08.16   Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

Pembro in combination with len and dex was associated with a tolerable safety profile and promising antimyeloma activity in heavily pretreated patients with RRMM.